Saponin-Linked Polyplexes for Endosomal Escape in Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current non-viral gene delivery systems face inefficiencies in delivering nucleic acids across the endosomal membrane into the cytosol and nucleosol, particularly for large genetic constructs, and lack targeted delivery to specific tissues, leading to insufficient therapeutic efficacy and safety concerns.
Innovation Solution
Development of saponin-equipped polyplexes with a covalently bound endosomal escape-enhancing saponin and a linker that releases under endosomal conditions, combined with a cell-targeting ligand for targeted delivery, forming either a 1-component or 2-component system.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If viral vectors are used for gene delivery, then delivery efficiency is improved, but safety concerns and immune responses increase
Solution Approach 1:
The patent replaces viral vectors with non-viral polymeric carriers that form polyplexes with nucleic acids. These synthetic carriers are designed to be transient and biodegradable, avoiding the persistent immune responses and safety concerns associated with viral vectors while maintaining delivery efficiency through controlled polymer design and endosomal escape mechanisms.
Solution Approach 2:
The invention uses composite polymeric scaffolds that combine multiple functional components: cationic polymers for nucleic acid binding, pH-sensitive linkers for endosomal escape, and targeting ligands for cell-specific delivery. This composite approach achieves viral-level delivery efficiency while avoiding viral safety issues through rational molecular design.
2Object-affected harmful factors
If non-viral polymeric carriers are used, then safety is improved, but cytosolic and nucleosolic uptake rates decrease
Solution Approach 1:
The patent employs pH-sensitive polymers and acid-labile linkers that undergo conformational or chemical changes in response to the acidic endosomal environment. This parameter change triggers polymer expansion, linker cleavage, and membrane disruption, enabling efficient endosomal escape and cytosolic release while maintaining safety through non-viral composition.
Solution Approach 2:
The polymeric carriers utilize protonation-induced conformational changes and polymer chain dynamics to mechanically disrupt endosomal membranes. The rapid pH-driven structural transitions create mechanical forces that facilitate membrane penetration and nucleic acid release into the cytosol, compensating for the generally lower uptake rates of non-viral systems.
3Reliability
If large genetic constructs are delivered, then therapeutic efficacy is improved, but transfection efficiency decreases
Solution Approach 1:
The patent designs polymeric scaffolds with segmented structures that include nucleic acid-binding domains, pH-sensitive release domains, and membrane-disruption domains. This segmentation allows the carrier to handle large genetic constructs by dividing the delivery function into modular components, maintaining transfection efficiency while accommodating therapeutically relevant gene sizes.
Solution Approach 2:
The polyplexes are pre-formed with large genetic constructs in vitro under optimized conditions, allowing thorough condensation and protection before cellular uptake. This preliminary assembly ensures that large therapeutic genes are properly packaged and protected during circulation, enabling efficient delivery and transfection without requiring optimization for each specific large construct.
4Stability of the object's composition
If cationic polymers are used for polyplex formation, then nucleic acid condensation is improved, but endosomal escape capability decreases
Solution Approach 1:
The patent uses cationic polymers with pH-sensitive side chains or incorporated acid-labile linkers that remain condensed at neutral pH but undergo expansion or degradation in acidic endosomes. This parameter change enables stable nucleic acid condensation during circulation while triggering automatic release and endosomal escape upon cellular internalization, resolving the contradiction between condensation stability and escape capability.
Solution Approach 2:
The invention introduces pH-sensitive linker molecules as intermediaries between the cationic polymer backbone and the nucleic acid. These linkers maintain stable polyplex formation at physiological pH but cleave in acidic endosomes, mediating the transition from stable condensation to active endosomal escape and cytosolic release.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances cytosolic delivery of nucleic acids, increases therapeutic efficacy, reduces toxicity, and allows for targeted gene therapy with improved safety and reduced production costs, suitable for systemic administration.
Implementation Method 1
a linker adapted to cleave and release the saponin from the polymeric scaffold under conditions present in an endosome
Implementation Method 2
stable synthetic carriers with high-affinity to NAs are employed, such as cationic polymers as well as cationic lipids. Such cationic polymers have the ability to spontaneously form through the electrostatic condensation interpolyelectrolyte high-density complexes with NAs, termed polyplexes
Data Source
AI summary
The invention lies in the field of delivery of nucleic acids into a cell. In particular, disclosed herein is a nucleic acid that is polyplexed with a polymeric scaffold, which is provided in combination with an endosomal escape-enhancing saponin that is covalently bound either to the polymeric scaffold or to a cell targeting ligand by a linker configured to release the saponin from the scaffold under conditions present in an endosome. The disclosed herein compositions and methods may be exploited in the treatment of various diseases and/or conditions by systemic delivery.